KOPS - The Institutional Repository of the University of Konstanz

Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease

Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease

Cite This

Files in this item

Files Size Format View

There are no files associated with this item.

DALVI, Tanay, Bhaskar DEWANGAN, Rudradip DAS, Jyoti RANI, Suchita D. SHINDE, Nazmina VHORA, Alok JAIN, Bichismita SAHU, 2020. Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease. In: Central Nervous System Agents in Medicinal Chemistry. Bentham Science Publishers. 20(3), pp. 157-176. ISSN 1871-5249. eISSN 1875-6166. Available under: doi: 10.2174/1871524920666201021164805

@article{Dalvi2020-10-21Drugs-52874, title={Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease}, year={2020}, doi={10.2174/1871524920666201021164805}, number={3}, volume={20}, issn={1871-5249}, journal={Central Nervous System Agents in Medicinal Chemistry}, pages={157--176}, author={Dalvi, Tanay and Dewangan, Bhaskar and Das, Rudradip and Rani, Jyoti and Shinde, Suchita D. and Vhora, Nazmina and Jain, Alok and Sahu, Bichismita} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/52874"> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dcterms:available> <dc:contributor>Dalvi, Tanay</dc:contributor> <dc:creator>Jain, Alok</dc:creator> <dc:creator>Dewangan, Bhaskar</dc:creator> <dc:contributor>Jain, Alok</dc:contributor> <dc:contributor>Das, Rudradip</dc:contributor> <dc:contributor>Rani, Jyoti</dc:contributor> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52874"/> <dc:creator>Sahu, Bichismita</dc:creator> <dc:creator>Dalvi, Tanay</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Vhora, Nazmina</dc:creator> <dcterms:issued>2020-10-21</dcterms:issued> <dc:creator>Das, Rudradip</dc:creator> <dc:contributor>Shinde, Suchita D.</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dc:date> <dc:contributor>Dewangan, Bhaskar</dc:contributor> <dc:contributor>Sahu, Bichismita</dc:contributor> <dc:contributor>Vhora, Nazmina</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/29"/> <dc:rights>terms-of-use</dc:rights> <dcterms:abstract xml:lang="eng">The most common reason behind dementia is Alzheimer's disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.</dcterms:abstract> <dc:creator>Shinde, Suchita D.</dc:creator> <dc:language>eng</dc:language> <dcterms:title>Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease</dcterms:title> <dc:creator>Rani, Jyoti</dc:creator> </rdf:Description> </rdf:RDF>

This item appears in the following Collection(s)

Search KOPS


Browse

My Account